The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Valsartan (Valent FC (80 mg)) is an angiotensin ...

Concomitant therapy with the following medications was prohibited: other ARBs, angiotensin-converting enzyme (ACE) inhibitors, β-adrenergic antagonists, calcium-channel blockers, any other ...

Morning hypertension has been reported to be an important risk factor for cardiovascular events, and arterial stiffness bears a relationship with cardiovascular risk. The aim of this study was to ...

The results of the Valsartan/HCTZ Combination Therapy in Patients With Moderate to Severe Systolic Hypertension (VALOR) study [1] show that valsartan 160 mg once daily is safe and effective in older ...

Earlier this month, the FDA announced a voluntary recall of some valsartan-containing drugs after N-nitrosodimethylamine (NDMA) was found in the active pharmaceutical ingredients (API) manufactured by ...

The new year brings a new blood pressure medication recall. This time Aurobindo Pharma USA has recalled 80 lots of its Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets USP and Valsartan ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Valsartan (Diovan (160 mg)) is an angiotensin II ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr.

Drug manufacturers are recalling several medications containing the ingredient valsartan, according to a press release from Health Canada on Tuesday. The drugs being recalled are used to treat ...

Atrial fibrillation is the most common cardiac arrhythmia, and no current therapy is ideal for control of this condition. Experimental studies suggest that angiotensin II–receptor blockers (ARBs) can ...

Sacubitril valsartan (Entresto, Novartis) has a UK marketing authorisation for 'the treatment of symptomatic chronic heart failure with reduced ejection fraction'. Before the marketing authorisation ...